Cargando…

The 46.1 Antibody Mediates Neurotensin Uptake into the CNS and the Effects Depend on the Route of Intravenous Administration

Central nervous system (CNS) exposure to blood-borne biotherapeutics is limited by the restrictive nature of the brain vasculature. In particular, tightly sealed endothelial cells of the blood–brain barrier (BBB) prevent the uptake of protein and gene medicines. An approach to increase the bioavaila...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgieva, Julia V., Katt, Moriah, Ye, Zhou, Umlauf, Benjamin J., Wenthur, Cody J., Shusta, Eric V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414616/
https://www.ncbi.nlm.nih.gov/pubmed/36015332
http://dx.doi.org/10.3390/pharmaceutics14081706
_version_ 1784776031916261376
author Georgieva, Julia V.
Katt, Moriah
Ye, Zhou
Umlauf, Benjamin J.
Wenthur, Cody J.
Shusta, Eric V.
author_facet Georgieva, Julia V.
Katt, Moriah
Ye, Zhou
Umlauf, Benjamin J.
Wenthur, Cody J.
Shusta, Eric V.
author_sort Georgieva, Julia V.
collection PubMed
description Central nervous system (CNS) exposure to blood-borne biotherapeutics is limited by the restrictive nature of the brain vasculature. In particular, tightly sealed endothelial cells of the blood–brain barrier (BBB) prevent the uptake of protein and gene medicines. An approach to increase the bioavailability of such therapeutics is harnessing the BBB endothelial cells’ own receptor-mediated transcytosis (RMT) mechanisms. Key to this process is a targeting ligand that can engage a BBB-resident RMT receptor. We recently identified an antibody, named 46.1, that accumulates in the mouse brain after intravenous injection. To further characterize the brain targeting and penetrating properties of clone 46.1, we conjugated neurotensin (NT) to an scFv-Fc form of the antibody (46.1-scFv-Fc-LongLinker-NT). While centrally administered NT decreases the core body temperature and locomotor activity, effects attributed to two spatially segregated brain areas, systemically administered NT has limited effects. Hence, NT can be used as a model therapeutic payload to evaluate the brain penetration of BBB-targeting antibodies and their capability to accumulate in discrete brain areas. We demonstrate that intravenously administered 46.1-scFv-Fc-LL-NT can elicit transient hypothermia and reduce drug-induced hyperlocomotion, confirming that 46.1 can deliver drug cargo to the CNS at pharmacologically relevant doses. Interestingly, when two intravenous administration routes in mice, retro-orbital and tail vein, were compared, only retro-orbital administration led to transient hypothermia. We further explored the retro-orbital route and demonstrated that the 46.1-scFv-Fc-LL-NT could enter the brain arterial blood supply directly from the retro-orbital/cavernous sinus. Taken together, the 46.1 antibody is capable of transporting drug cargo into the CNS, and at least of a portion of its CNS accumulation occurs via the cavernous sinus–arterial route.
format Online
Article
Text
id pubmed-9414616
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94146162022-08-27 The 46.1 Antibody Mediates Neurotensin Uptake into the CNS and the Effects Depend on the Route of Intravenous Administration Georgieva, Julia V. Katt, Moriah Ye, Zhou Umlauf, Benjamin J. Wenthur, Cody J. Shusta, Eric V. Pharmaceutics Article Central nervous system (CNS) exposure to blood-borne biotherapeutics is limited by the restrictive nature of the brain vasculature. In particular, tightly sealed endothelial cells of the blood–brain barrier (BBB) prevent the uptake of protein and gene medicines. An approach to increase the bioavailability of such therapeutics is harnessing the BBB endothelial cells’ own receptor-mediated transcytosis (RMT) mechanisms. Key to this process is a targeting ligand that can engage a BBB-resident RMT receptor. We recently identified an antibody, named 46.1, that accumulates in the mouse brain after intravenous injection. To further characterize the brain targeting and penetrating properties of clone 46.1, we conjugated neurotensin (NT) to an scFv-Fc form of the antibody (46.1-scFv-Fc-LongLinker-NT). While centrally administered NT decreases the core body temperature and locomotor activity, effects attributed to two spatially segregated brain areas, systemically administered NT has limited effects. Hence, NT can be used as a model therapeutic payload to evaluate the brain penetration of BBB-targeting antibodies and their capability to accumulate in discrete brain areas. We demonstrate that intravenously administered 46.1-scFv-Fc-LL-NT can elicit transient hypothermia and reduce drug-induced hyperlocomotion, confirming that 46.1 can deliver drug cargo to the CNS at pharmacologically relevant doses. Interestingly, when two intravenous administration routes in mice, retro-orbital and tail vein, were compared, only retro-orbital administration led to transient hypothermia. We further explored the retro-orbital route and demonstrated that the 46.1-scFv-Fc-LL-NT could enter the brain arterial blood supply directly from the retro-orbital/cavernous sinus. Taken together, the 46.1 antibody is capable of transporting drug cargo into the CNS, and at least of a portion of its CNS accumulation occurs via the cavernous sinus–arterial route. MDPI 2022-08-16 /pmc/articles/PMC9414616/ /pubmed/36015332 http://dx.doi.org/10.3390/pharmaceutics14081706 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Georgieva, Julia V.
Katt, Moriah
Ye, Zhou
Umlauf, Benjamin J.
Wenthur, Cody J.
Shusta, Eric V.
The 46.1 Antibody Mediates Neurotensin Uptake into the CNS and the Effects Depend on the Route of Intravenous Administration
title The 46.1 Antibody Mediates Neurotensin Uptake into the CNS and the Effects Depend on the Route of Intravenous Administration
title_full The 46.1 Antibody Mediates Neurotensin Uptake into the CNS and the Effects Depend on the Route of Intravenous Administration
title_fullStr The 46.1 Antibody Mediates Neurotensin Uptake into the CNS and the Effects Depend on the Route of Intravenous Administration
title_full_unstemmed The 46.1 Antibody Mediates Neurotensin Uptake into the CNS and the Effects Depend on the Route of Intravenous Administration
title_short The 46.1 Antibody Mediates Neurotensin Uptake into the CNS and the Effects Depend on the Route of Intravenous Administration
title_sort 46.1 antibody mediates neurotensin uptake into the cns and the effects depend on the route of intravenous administration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414616/
https://www.ncbi.nlm.nih.gov/pubmed/36015332
http://dx.doi.org/10.3390/pharmaceutics14081706
work_keys_str_mv AT georgievajuliav the461antibodymediatesneurotensinuptakeintothecnsandtheeffectsdependontherouteofintravenousadministration
AT kattmoriah the461antibodymediatesneurotensinuptakeintothecnsandtheeffectsdependontherouteofintravenousadministration
AT yezhou the461antibodymediatesneurotensinuptakeintothecnsandtheeffectsdependontherouteofintravenousadministration
AT umlaufbenjaminj the461antibodymediatesneurotensinuptakeintothecnsandtheeffectsdependontherouteofintravenousadministration
AT wenthurcodyj the461antibodymediatesneurotensinuptakeintothecnsandtheeffectsdependontherouteofintravenousadministration
AT shustaericv the461antibodymediatesneurotensinuptakeintothecnsandtheeffectsdependontherouteofintravenousadministration
AT georgievajuliav 461antibodymediatesneurotensinuptakeintothecnsandtheeffectsdependontherouteofintravenousadministration
AT kattmoriah 461antibodymediatesneurotensinuptakeintothecnsandtheeffectsdependontherouteofintravenousadministration
AT yezhou 461antibodymediatesneurotensinuptakeintothecnsandtheeffectsdependontherouteofintravenousadministration
AT umlaufbenjaminj 461antibodymediatesneurotensinuptakeintothecnsandtheeffectsdependontherouteofintravenousadministration
AT wenthurcodyj 461antibodymediatesneurotensinuptakeintothecnsandtheeffectsdependontherouteofintravenousadministration
AT shustaericv 461antibodymediatesneurotensinuptakeintothecnsandtheeffectsdependontherouteofintravenousadministration